Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Progress in Parasite Genomics and Its Application to Current Challenges in Malaria Control

“…Preventing the invasion of sporozoites will inhibit the progression and severity of the disease. Using the C-terminus and central tandem repeat (NANP) of PfCSP, Hepatitis B surface membrane antigen (HSbAg), and an AS01 adjuvant system, the vaccine will elicit a strong, stable immune response [94]. After vaccination, the host immune system will response to PfCSP antigen by producing anti-CSP antibodies and activating CD4+ T cells [95].…”

“…After vaccination, the host immune system will response to PfCSP antigen by producing anti-CSP antibodies and activating CD4+ T cells [95]. RTS,S/AS01E is given on a three-dose schedule within three months followed by a fourth dose at 20 months [94]. It has been shown across clinical malarial studies that the vaccine has an 39-50% efficacy in children ages 5-17 months and 23-30% efficacy in children ages 6-12 months [96][97][98].…”

“…It has been shown across clinical malarial studies that the vaccine has an 39-50% efficacy in children ages 5-17 months and 23-30% efficacy in children ages 6-12 months [96][97][98]. Efficacy warned rapidly from 35.2% and 20.3% to 19.1% and 12.7%, respectively, in children and infants within 20-32 months without a booster [94]. Such a decay in vaccine efficacy could be due to reduced IgG and IgM antibodies against CSP antigen.…”